Objectives To observe the influence of weight loss induced by orlistat on several cardiovascular diseases risk factors in obese Chinese subjects. Methods Sixty obese Chinese patients participated in a 24 week clinical...Objectives To observe the influence of weight loss induced by orlistat on several cardiovascular diseases risk factors in obese Chinese subjects. Methods Sixty obese Chinese patients participated in a 24 week clinical trial. Participants were prescribed a slightly hypocaloric diet and exercise, then they were randomly assigned double -blind treatment with either orlistat 120 mg three times a day or placebo. Their body weight, blood pressure, fasting glucose, insulin, HbA1c, and serum lipid profile were performed before and after the weight loss intervention. Results After 24 weeks, orlistat -treated group lost more of their body weight than placebo group (6. 66 ± 0. 52 kg, 8. 44±4.08% and 1. 98 ± 0. 44 kg, 2. 44±1. 74 % , respectively, P < 0. 05) . Moreover, after treatment, orlistat - treated patients showed significant decreases in serum levels of total cholesterol, low density lipoprotein - cholesterol and high density lipoprotein - cholesterol ( P < 0.01), but in placebo group we found no change. Both systolic blood pressure and diastolic blood pressure fell significantly in orlistat - treated group. Fasting glucose and HOMA - IR in orlistat - treated group was distinctly reduced if compared with placebo group. Conclusions Weight loss resulting from orlistat treatment and slightly hypocaloric diet has produced favorable effects on several cardiovascular risk factors in obese Chinese subjects.展开更多
文摘Objectives To observe the influence of weight loss induced by orlistat on several cardiovascular diseases risk factors in obese Chinese subjects. Methods Sixty obese Chinese patients participated in a 24 week clinical trial. Participants were prescribed a slightly hypocaloric diet and exercise, then they were randomly assigned double -blind treatment with either orlistat 120 mg three times a day or placebo. Their body weight, blood pressure, fasting glucose, insulin, HbA1c, and serum lipid profile were performed before and after the weight loss intervention. Results After 24 weeks, orlistat -treated group lost more of their body weight than placebo group (6. 66 ± 0. 52 kg, 8. 44±4.08% and 1. 98 ± 0. 44 kg, 2. 44±1. 74 % , respectively, P < 0. 05) . Moreover, after treatment, orlistat - treated patients showed significant decreases in serum levels of total cholesterol, low density lipoprotein - cholesterol and high density lipoprotein - cholesterol ( P < 0.01), but in placebo group we found no change. Both systolic blood pressure and diastolic blood pressure fell significantly in orlistat - treated group. Fasting glucose and HOMA - IR in orlistat - treated group was distinctly reduced if compared with placebo group. Conclusions Weight loss resulting from orlistat treatment and slightly hypocaloric diet has produced favorable effects on several cardiovascular risk factors in obese Chinese subjects.
文摘目的:观察单侧双通道内镜下腰椎融合术(unilateralbiportal endoscopic transforaminal lumbarinter-bodyfusion,UBE-TLIF)术后的隐性失血情况,并对其相关危险因素进行分析。方法:回顾性分析2020年1月~2021年6月在我院行UBE-TLIF治疗的59例腰椎退行性疾病患者的临床资料,收集患者一般资料如年龄、性别、体质指数(bodymass index,BMI)、学习曲线、疾病类型以及是否合并有高血压、糖尿病;手术相关资料如病变节段、手术时间、显性失血量、美国麻醉师协会麻醉分级(American Society of Anesthesiologists,ASA);实验室检查如凝血酶原时间、活化部分凝血活酶时间、血小板计数、纤维蛋白原、血红蛋白(hemoglobin,Hb)和红细胞压积(hematocrit,Hct)。根据Gross公式计算总失血量,并由此计算患者的术后隐性失血量,采用单因素方差分析和Pearson相关性检验探讨患者的特征与术后隐性失血之间的相关性,采用多元线性回归分析确定术后隐性失血的独立危险因素,构建危险因素的受试者工作特征(receiver operating characteristic,ROC)曲线以分析危险因素的预测价值。结果:手术时间为128.22±22.88min,总失血量为607.32±186.78ml,隐性失血量为393.83±173.42ml,占总失血量的(62.13±11.73)%。术后Hb、Hct均较术前明显降低(P<0.05)。单因素方差分析中性别、高血压、糖尿病、手术节段、疾病类型与隐性失血无明显相关性(P>0.05),学习曲线和ASA分级与隐性失血具有相关性(P<0.001)。Pearson相关性分析显示,年龄、BMI、凝血酶原时间、活化部分凝血活酶时间、血小板计数与隐性失血无相关性(P>0.05),手术时间、纤维蛋白原与隐性失血具有相关性(P<0.001)。多元线性回归分析显示,手术时间(B=2.236,P<0.01)学习曲线(B=-109.781,P<0.01)、ASA分级(B=77.589,P<0.01)和纤维蛋白原(B=81.762,P<0.01)是隐性失血的独立危险因素。ROC曲线显示手术时间预测严重隐性失血的ROC曲线下面积(areaundercurve,AUC)为0.813(95%CI:0.688~0.938,P<0.001),最佳截点为139.5min;纤维蛋白原的AUC为0.794(95%CI:0.654~0.934,P<0.001),最佳截点为2.65g/L。结论:UBE-TLIF治疗腰椎退行性疾病存在较大的术后隐性失血,手术时间、学习曲线、ASA分级和纤维蛋白原是术后隐性失血的独立危险因素。